A well defined and manageable safety profile1
<1% of the overall patient population discontinued due to diarrhoea1
†19 patients discontinued bosutinib due to neutropenia
Safety events for study population exposed to bosutinib/imatinib
Please refer to the BOSULIF SmPC for full details of adverse events
AE, adverse event; ALL, acute lymphoblastic leukaemia; ALT, alanine aminotransferase; AP, accelerated phase; AST, aspartate aminotransferase; BP, blast phase; CML, chronic myeloid leukaemia; CP, chronic phase; Ph+, Philadelphia chromosome-positive; SmPC, Summary of Product Characteristics.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021